ReGenTree, LLC, a U.S. joint venture company owned by GtreeBNT Co., Ltd, and RegeneRx Biopharmaceuticals, Inc., announced the results of a randomized, double masked, placebo-controlled Phase 3 clinical trial using RGN-259 for the treatment of neurotrophic keratopathy.
May 14, 2020
· 4 min read